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Serpins (serine proteinase inhibitors) are an ancient superfamily of structurally similar pro-
teins, the majority of which use an elegant suicide inhibition mechanism to target serine
proteinases. Despite likely evolving from a single common ancestor, the 36 human
serpins have established roles regulating diverse biological processes, such as blood
coagulation, embryonic development and extracellular matrix (ECM) turnover. Genetic
mutations in serpin genes underpin a host of monogenic disorders — collectively termed
the ‘serpinopathies’ — but serpin dysregulation has also been shown to drive patho-
logical mechanisms in many common diseases. Osteoarthritis is a degenerative joint dis-
order, characterised by the progressive destruction of articular cartilage. This breakdown
of the cartilage is driven by the metalloproteinases, and it has long been established that
an imbalance of metalloproteinases to their inhibitors is of critical importance. More
recently, a role for serine proteinases in cartilage destruction is emerging; including the
activation of latent matrix metalloproteinases and cell-surface receptors, or direct prote-
olysis of the ECM. Serpins likely regulate these processes, as well as having roles
beyond serine proteinase inhibition. Indeed, serpins are routinely observed to be highly
modulated in osteoarthritic tissues and fluids by ‘omic analysis, but despite this, they are
largely ignored. Confusing nomenclature and an underappreciation for the role of serine
proteinases in osteoarthritis (OA) being the likely causes. In this narrative review, serpin
structure, biochemistry and nomenclature are introduced, and for the first time, their puta-
tive importance in maintaining joint tissues — as well as their dysregulation in OA — are
explored.
Introduction
The serpin (serine proteinase inhibitor) superfamily of proteins is both ancient and unique. Found in
all five kingdoms of life, they are likely to have evolved from a single common ancestor — termed ‘the
archeserpin’ — approximately 500 million years ago [1,2]. Despite individual serpins being described
for over a century, it was not until the early 1980s that structural similarities were observed between
remarkably different proteins, when a unique protein family was uncovered [3]. The term ‘serpin’ was
coined later, due to the observed antiproteinase activity [4] but it is now well understood that serpins
can be both inhibitory or non-inhibitory.
Serpin structure, mechanism, nomenclature and evolution
There are 36 protein-coding serpin family members in humans, of which 30 can inhibit proteinases
[5]. Serpins are subdivided into ‘clades’ — A through to I — based on sequence similarity (Table 1).
Outside of these groups, serpins exhibit surprisingly little sequence similarity, except for some con-
served residues (e.g. Ser53 and Ser56) within the ‘shutter region’ in the core of the protein. This is an
area of critical importance for the serpin mechanism, which is highlighted by mutations in these
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positions leading to several serious human serpinopathies; a collection of diseases resulting from serpin dys-
function [6]. However, despite only low sequence similarity, serpins are remarkably similar structurally; usually
consisting of 7–9 α-helices surrounding 3 β-sheets and a large flexible region above the body of the protein,
known as the reactive centre loop (RCL).











SerpinA2 Alpha-1 antitrypsin-related protein EKAW⇣SKYQ
SerpinA3 Alpha-1 antichymotrypsin ITLL⇣SALV Cathepsin G
SerpinA4 Kallistatin IKFF⇣SAQT Tissue kallikrein
SerpinA5 Protein C inhibitor FTFR⇣SARL Activated protein C
SerpinA6 Corticosteroid-binding globulin Non-inhibitory
SerpinA7 Thyroxin-binding protein Non-inhibitory
SerpinA8 Angiotensinogen Non-inhibitory
SerpinA9 Centerin FIVR⇣SKDG —
SerpinA10 Protein-Z dependent proteinase inhibitor ITAY⇣SMPP Factor Xa; Factor XIa
SerpinA11 —
SerpinA12 Vaspin TLPM⇣ETPL Kallikrein 7






SerpinB2 Plasminogen-activator inhibitor (PAI-2) MTGR⇣TGHG uPA
SerpinB3 Squamous cell carcinoma antigen 1
(SCCA1)
GFGS⇣SPTS Cathepsin K, cathepsin L,
cathepsin S
SerpinB4 Squamous cell carcinoma antigen 2
(SCCA2)
VVEL⇣SSPS Cathepsin G, chymase
SerpinB5 Maspin Non-inhibitory





SerpinB8 Cytoplasmic antiproteinase 2 (CAP2) RNSR⇣CSRM Furin, thrombin, subtilisin A
SerpinB9 Cytoplasmic antiproteinase 3 (CAP3) VVAE⇣CCME Granzyme B, caspase 1,
subtilisin A
SerpinB10 Bomapin IDIR⇣IRVP Thrombin
SerpinB11 Epipin IAVK⇣SLPM
SerpinB12 Yukopin VSER⇣SLRS Trypsin, plasmin
SerpinB13 Headpin FTVT⇣SAPG
Clade C SerpinC1 Antithrombin IAGR⇣SLNP Thrombin; Factor Xa
Clade D SerpinD1 Heparin cofactor II FMPL⇣STQV Thrombin
Clade E SerpinE1 Plasminogen-activator inhibitor 1 VSAR⇣MAPE Plasminogen activators (tPA;
uPA)
SerpinE2 Protease nexin-1 LIAR⇣SSPP Plasminogen activators (tPA;
uPA), thrombin
SerpinE3 — LLKR⇣SRIP —
Clade F SerpinF1 Pigment epithelial-derived factor Non-inhibitory
SerpinF2 Alpha-2 antiplasmin AMSR⇣MSLS Plasmin
Clade G SerpinG1 C1-inhibitor SVAR⇣TLLV C1 proteinase
Clade H SerpinH1 HSP-47 Non-inhibitory
Clade I SerpinI1 Neuroserpin AISR⇣MAVL Plasmin, plasminogen
activators (tPA; uPA)
SerpinI2 Myoepithelium-derived serine proteinase
inhibitor (MEPI); Pancpin
IPVI⇣MSLA
For inhibitory serpins, the reactive centre loop (RCL) sequences are defined as P4–P40, where (⇣) is the cleavage site for the target proteinase. Previously identified targets
are also listed. List modified from [1,5,11] and RCL sequences confirmed using the UniProt Knowledgebase [46].
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Inhibitory serpins have an elegant mode of inhibition. Monomeric, serpins exist in a constrained (metastable,
M-state) conformation until they interact with a proteinase. Often described as ‘molecular mousetraps’, the
RCL of inhibitory serpins acts as a ‘bait region’ which contains a sequence of amino acids targeted by specific
proteinase(s) [7]. Upon initiation of cleavage, the serpin undergoes a rapid switch, whereby the RCL is inserted
into a β-sheet within the main body of the serpin [8–10]. As this occurs prior to the ‘deacylation’ step of prote-
olysis, the proteinase remains covalently attached to the serpin as an acyl-enzyme intermediate. This mode of
suicide inhibition involves a huge conformational change which moves the proteinase ∼70 Å to the other side
of the serpin protein [9] and renders a hyperstable serpin : proteinase complex (relaxed; R-state). The molecular
dynamics of the serpin mechanism has both perplexed and fascinated the structural biology field for decades,
and has been investigated and reviewed extensively elsewhere (see [11,12]). Interestingly, evolutionary analyses
suggest that different serpins have emerged through gene duplication events, evolving by speciation to perform
particular physiological roles, rather than specific inhibition of a proteinase [1,6]. The crystal structures in
Figure 1 depict the important regions of the serpin and the structural changes which occur upon complex for-
mation with a target proteinase.
Cartilage destruction in osteoarthritis
Cartilage is a tissue which covers the end of long bones, lacks any vasculature or innervation, and has a single
cell type — the chondrocyte. Composed of an organised extracellular matrix (ECM), it consists predominantly
of type II collagen providing structural integrity, and the proteoglycan aggrecan, which provides compressive
strength through osmotic water retention. Central to osteoarthritis (OA) is the destruction of this tissue and the
exposure of the underlying bone, a process driven by metalloproteinases [13]. In particular, a disintegrin and
metalloproteinase with thrombospondin motifs (ADAMTS) enzymes drive the initial loss of cartilage aggrecan,
Figure 1. Serpin structure and inhibitory mechanism.
Despite significant differences in sequence, the serpin superfamily display remarkable structural similarity. Serpins have 2–3
β-sheets surrounded by 7–9 α-helices and a reactive centre loop (RCL), which acts as a bait region for inhibitory serpins. Some
conserved residues do exist amongst family members, for example, in the shutter region. Serpin inhibition begins with
proteolytic attack of the RCL by a proteinase. Under normal circumstances, cleavage by a serine proteinase involves the
formation of a covalent acyl-enzyme intermediate, followed by a deacylation step to release the cleaved products. In serpin
inhibition, initial interaction with a proteinase is followed by the rapid and significant conformational of the serpin and distortion
of the enzyme active site, such that deacylation cannot occur. This results in a hyperstable, covalent serpin:proteinase complex
(right). Figure generated in PyMol, using structures imported from the Protein Data Bank — ID 1QLP [12], left; 1EZX [10], right.
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while matrix metalloproteinase (MMPs) can together degrade all the components of cartilage. Of these, in par-
ticular, it is the soluble collagenases, such as MMP-13, which are responsible for pathological collagen cleavage.
Metalloproteinases are inhibited by a cognate family of inhibitors, the tissue inhibitor of metalloproteinases
(TIMPs), of which there are four in humans (TIMP-1, -2, -3 -4) and provide a delicate balance between synthe-
sis and degradation.
More recently important roles for a different family of extracellular proteinases — the serine proteinases —
has emerged in OA. Serine proteinases can activate proMMPs, cleave cellular receptors and cytokines as well as
destroy the ECM directly [14–18]. The largest family of inhibitors of these proteinases are the serpins, which
until now have not been interrogated collectively in this tissue. This review is not exhaustive, but will cover
important studies relating to this unique superfamily of proteins in cartilage biology and OA. The currently
identified roles for serpins in this context are summarised in Figure 2.
Serpins in cartilage and osteoarthritis
Clade A — the ‘antitrypsin-like’ serpins
This clade forms the largest extracellular serpin sub group; containing 11 genes and 2 pseudogenes [1]. Perhaps
the most studied members of this clade are SerpinA1 (also known as alpha-1 antitrypsin or alpha-1 proteinase
inhibitor) and SerpinA3 (alpha-1 antichymotrypsin). These serpins inhibit several proteinases but association
kinetics are most favourable for the neutrophil serine proteinases (NSPs) — neutrophil elastase and
proteinase-3 in the case of SerpinA1, and cathepsin G for SerpinA3 [19]. Both serpins are described as ‘acute
phase’ proteins, which are synthesised upon initiation of systemic inflammation — predominantly by the liver
— and function to down-regulate the inflammatory response [20]. Interestingly, both SerpinA1 and SerpinA3
are abundantly expressed by chondrocytes [21]. Perhaps underscoring the importance of SerpinA1 and
SerpinA3 in cartilage biology, both are also markedly induced during chondrogenic differentiation from
Figure 2. The putative roles and regulation of serpins in the joint.
Abbreviated common names are shown in brackets for reference: SerpinA1 — AAT (alpha-1 antitrypsin); SerpinA9 (Centerin) —
SerpinA3 — ACT (alpha-1 antichymotrypsin); SerpinB2 — PAI-2 (plasminogen Activator Inhibitor-2); SerpinC1 — AT
(antithombin); SerpinD1 — HC-II (heparin cofactor II); SerpinE1 — PAI-1 (plasminogen activator inhibitor-1); SerpinE2 — PN-1
(protease nexin-1); SerpinF1 — PEDF (pigment epithelium-derived factor); SerpinF2 — A2AP (alpha-2 antiplasmin); SerpinH1
— HSP47 (heat shock protein 47).
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mesenchymal stem cells, and have been previously earmarked as putative differentiation markers [22]. In add-
ition, SerpinA9 (centerin) is also induced when chondrogenesis is stimulated by kartogenin ex vivo [23]. It is
not yet clear what if any role these serpins have in chondrogenesis and whether this is due to their inhibitory
function. Indeed, both SerpinA1 and SerpinA3 have important functions outside of their inhibitory activity
which could be important within the context of cartilage biology [24,25].
As early phase proteins, it is perhaps unsurprising that levels of SerpinA1 and SerpinA3 have been shown to
be increased in the serum and synovial fluid of rheumatoid arthritis patients [26] and SerpinA1 expression is
increased in response to inflammatory cytokines in chondrocytes [27]. However, the expression of this serpin
appears to be reduced in OA cartilage, and lower levels have been observed in OA synovial fluid compared
with non-OA controls [22,28]. Intraperitoneal injection of SerpinA1 protects against destruction in the
collagen-induced arthritis model of inflammatory arthritis [29], and this serpin can block collagen release from
cytokine-stimulated bovine cartilage ex vivo [30]. The localisation of both SerpinA1 and SerpinA3 within the
cartilage may also provide insights as to their function in the tissue. A cross-sectional quantitative proteomic
study of cartilage observed that both serpins were located predominantly in the superficial cartilage layer [31].
This perhaps reflects a well-positioned defence against damaging neutrophil proteinases, which through knock-
out studies have been shown to be essential for the progression of collagen-induced arthritis, a model of
rheumatoid arthritis [32]. Emerging evidence suggests proteinases such as neutrophil elastase may also have a
role in OA [33–35] meaning changes in levels of these serpins might be of particular importance in this
context.
Clade B — the intracellular serpins
Even amongst the serpin superfamily, the clade B serpins are unique. Lacking a signal peptide, they form an
intracellular clade, which likely predates extracellular serpins [1]. Despite this, several studies have reported
clade members extracellularly, suggesting other modes of secretion into the extracellular space, beyond the clas-
sical secretory pathway [36]. They show remarkable similarity in gene structure across the clade (8 exons, 7
introns) and are present in mammals and birds, but not in earlier model organisms such as Caenorhabditis
elegans or Drosophila melanogaster, leading to suggestions the clade is at least 300 million years old [36].
Members of this clade have diverse roles including regulating cell growth, apoptosis, immunity and protecting
cells from intracellular proteolysis [37]. Few studies have investigated B clade serpins in cartilage, although it
has been shown that SerpinB2 (plasminogen activator inhibitor (PAI)-2), like SerpinA9, is markedly induced
during cartilage formation following MSC treatment with kartogenin [23]. Interestingly, proteomic analyses of
urine suggest that SerpinB1 (leukocyte elastase inhibitor; LEI) and SerpinB3 were both significantly down-
regulated in older patients with OA compared with urine from younger healthy controls without OA [38].
Clade C — antithrombin
This clade has just one member, SerpinC1 (commonly known as antithrombin), which acts a major inhibitor
of coagulation enzymes and has a circulating blood concentration of 0.15 g/l [39]. SerpinC1 is poorly expressed
by chondrocytes [21], but this serpin is detectable in synovial fluid with increased SerpinC1 : proteinase com-
plexes observed in both the OA and RA patients [40]. Interestingly, SerpinC1 requires heparin for maximal
inhibitory activity, which is commonly administered as an antithrombotic. This glycosaminoglycan (GAG)
increases the association constant approximately 300-fold, resulting from a shift in the main sheets within the
serpin core, and an extrusion of the RCL, making it more exposed to proteolytic attack [41]. The potential sig-
nificance of cartilage-derived GAGs in regulating serpin activity is explored further in section ‘ECM binding’.
Clade D — heparin cofactor II
This clade also only contains one member — SerpinD1 (also known as Heparin Cofactor II) which is rapid
inhibitor of thrombin, but like SerpinC1, only in the presence of GAGs; including heparin, heparan sulfate or
dermatan sulfate. Despite sharing 30% sequence identity with SerpinC1, little is known about its physiological
function, although a role in the response to vascular injury is likely [42,43]. SerpinD1 has been shown to bind
strongly to the small leucine-rich proteoglycans decorin and bigylcan [44], both of which are abundant in car-
tilage. Proteomic analysis of synovial fluid has demonstrated that SerpinD1 is elevated in OA compared with
healthy controls [45].
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Clade E — plasminogen activator inhibitor-1 and proteinase nexin-1
This clade is home to three serpins, only two of which are well described — SerpinE1 (plasminogen activator
inhibitor-1) and SerpinE2 (protease nexin-1). These serpins share 40% sequence identity and significant struc-
tural overlap [46]. Like many serpins, they target trypsin-like serine proteinases due to an arginine residue in
the P1 position in their RCL [5] but they also share an additional commonality in other RCL amino acids
(Table 1). SerpinE1 is a well-established regulator of fibrinolysis through inhibition of urokinase and tissue-type
plasminogen activators (uPA and tPA, respectively; [47]). SerpinE2 is also a potent inhibitor of uPA, as well as
the coagulation proteinase, thrombin [48]. It is important to recognise that despite the biochemical similarities,
the physiological functions of these serpins display marked differences, perhaps best evidenced by phenotypes
of mice deficient for these serpins. SerpinE1−/− mice display altered clot lysis [49], whilst SerpinE2−/− mice
display neurological abnormalities and males are infertile [50,51]. As with the clade A serpins, both SerpinE1
and SerpinE2 are induced by pro-inflammatory cytokines in chondrocytes [52–54] and SerpinE1 has been
shown to be induced by both mechanical loading and fluid shear stress [55,56]. In OA, some studies have
observed decreased levels of both SerpinE1 [57] and SerpinE2 [21] in the cartilage, perhaps suggesting an
increased proteolytic load. Indeed, we have demonstrated that both serpins are able to protect against cartilage
collagen breakdown in an ex vivo model of cartilage destruction, likely through the inhibition of proteolytic
activators of MMPs (as yet unpublished observations). Intra-articular SerpinE2 administration was also able to
protect against joint destruction in a rabbit model [58]. Santoro and colleagues demonstrated that SerpinE2 can
block interleukin (IL)-1 induced expression of MMP-13 in chondrocytes, in a mechanism which appears to
involve ERK, NFκB and AP-1 [53] with similar observations demonstrated in the cartilage of the intervertebral
disc [59]. Neither study investigates the involvement of serine proteinases in these observations, and it is pos-
sible that SerpinE2 may have chondroprotective roles outside of proteinase inhibition. Interestingly, an inverse
observation has been made for SerpinE1, as murine chondrocytes from SerpinE1−/− mice show a reduction in
IL-1 induced Mmp13 expression [60]. These mice also display accelerated subchondral osteopenia compared
with wild-type mice following surgical induction of OA in ovariectomized female mice [61].
The effect of clade E serpin genes on joint pathology is not exclusively at the protein level. In 2019, Shen
and colleagues identified a circular RNA (circSERPINE2) which is down-regulated in OA and appears to regu-
late catabolic factors in the cartilage, acting as a sponge for microRNAs. The authors demonstrated that adeno-
viral overexpression of circSERPINE2 was able to protect cartilage in a rabbit OA model [62].
Clade F — pigment derived epithelial factor and alpha-2 antiplasmin
This clade consists of 2 members SerpinF1 and SerpinF2. SerpinF1 is perhaps better known as pigment
epithelium-derived factor (PEDF). Devoid of inhibitory activity, this serpin has anti-angiogenic, neurotrophic
and differentiation-inducing properties, and numerous studies have described its role cancer [63]. SERPINF1
acts predominantly through the cognate receptor PEDFR, and its action appears to be highly regulated by
binding to ECM components [64–66]. In the joint, the role of SerpinF1 is catabolic, promoting cartilage destruc-
tion. Indeed, SerpinF1 has been reported to be increased in OA cartilage [45], and a recent study demonstrated
that SerpinF1 deficiency reduces cartilage damage in an age-dependent manner in the murine monoiodoaceta-
mide OA model, and overexpression in chondrocytes enhances cytokine-induced expression of catabolic MMPs
[67]. In support of these observations, a different study demonstrated that stimulation of chondrocytes with
recombinant SERPINF1 led to a catabolic phenotype and chondrocyte terminal differentiation [68].
The other serpin in this clade, SerpinF2 (also known as alpha-2 antiplasmin) is the primary inhibitor of
plasmin, a proteinase which functions to cleave fibrin to promote clot disruption. Plasmin can also activate
MMPs and contribute to ECM turnover [14]. In haemophilic mice, it has been demonstrated than fibrinolytic
proteinases are liberated from the synovium during hemoarthrosis [69] and that intra-articular SerpinF2
administration was able to reduce cartilage damage and synovitis [70]. Any protective effect of this SerpinF2 in
the OA joint has not yet been investigated, however.
Clade H — HSP47 — an essential collagen chaperone
The only serpin in its clade, SerpinH1 (also known as heat shock protein (Hsp)47) is a non-inhibitory serpin
which has a primary function as a collagen chaperone within the endoplasmic reticulum (ER). Unlike other
chaperones, this serpin appears to have only one client protein, and binds at regular sites along the collagen
triple helix [71]. Cells deficient for this protein show accumulation of collagen aggregates in the ER [72]. It is,
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).1018
Biochemical Society Transactions (2021) 49 1013–1026
https://doi.org/10.1042/BST20201231
therefore, essential for new collagen synthesis and normal cartilage development and homeostasis. Indeed,
homozygous missense mutations in the SERPINH1 gene result in osteogenesis imperfecta [73] and mice defi-
cient for SerpinH1 die shortly after birth, exhibiting generalised chondrodysplasia and bone abnormalities [74].
Phylogenetic analysis demonstrates the SERPINH1/HSP47 gene to be present in cartilaginous fish such as the
Japanese lamprey, dating back approximately 500 million years [75].
A role for SerpinH1 in OA is not yet clear. Changes in levels of collagen synthesis during different stages of
cartilage catabolism in OA are, however, well described [76]. The corollary of which is that an essential collagen
chaperone will also have an important role in such changes, but this has not yet been determined experimentally.
Common modes of serpin regulation and their implications
for joint tissues
Serpin proteins display exceptional characteristics both structurally and evolutionary. Perhaps as a result, many
members also share common modes of regulation as summarised in Figure 3.
ECM binding
Cartilage ECM is rich in proteoglycan; predominantly aggrecan, but also more minor components such as
biglycan, decorin and perlecan. GAG chains provide the correct osmotic potential in the cartilage to retain
water and resist compression, but they also act as a major regulators of cartilage ECM proteins, including both
metalloproteinases and their inhibitors [77,78]. GAGs can not only bind and sequester serpins, but for some
also enhance their inhibitory activity, by causing large changes in conformation, making proteolytic attack of
the RCL more favourable (see [79]). Many serpins are recognised as binding to GAGs and protein structures
are often crystallised in complex with them (usually heparin; [48,80]). It is plausible that serpin inhibitory
activity can be enhanced in the presence of GAGs within cartilage, and as our understanding of the role of
serpins in this tissue improves, so too will their association with, and the relevance of, particular cartilage GAG
chains. Sulphation patterns of GAGs are critical to the binding of serpin exosites [81]. In cartilage, sulphation
has been shown to be important for GAG binding of ADAMTS-5 and TIMP-3 [78], and the sulphation
pattern of important cartilage GAGs changes in OA, which may impact on their function in the tissue [82,83].
Figure 3. Modes of serpin protein regulation with direct relevance to joint tissues and osteoarthritis.
(A) At the protein level, serpins are well described GAG-binding proteins, the interaction with which can significantly alter their
inhibitory capacity. Cartilage is rich in sulfated GAG in proteoglycans such as aggrecan. (B) Endocytosis is emerging as a
major regulator of the levels of proteinases and their inhibitors in cartilage. ADAMTS-4, ADAMTS-5, MMP-13 and TIMP-3 are
all endocytosed by LRP-1 in chondrocytes, and increased shedding of the LRP-1 receptor in OA has likely importance for the
regulation of cartilage matrix proteolysis. Several serpins are well-described ligands for LRP-1 in other tissues. (C) Specific
inactivation of serpins by MMPs occurs in close proximity to the canonical serine proteinase cleavage site. This results in
disarming of the serpin by removal of the RCL. Active MMPs in the OA joint likely contribute to the proteolytic burden by
significant inactivation of serpins.
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Endocytosis
Endocytosis is becoming established as a mode of metalloproteinase regulation in cartilage and OA. The endo-
cytic receptor LRP-1 is a large transmembrane protein which plays a critical role in the regulation of MMPs,
ADAMTS proteinases and TIMPs by binding and removing them from the extracellular space [84–87]).
Indeed, there is evidence that LRP-1 and GAGs compete for the binding of TIMP-3 [78]. Serpin binding to
LRP-1 is well established; initial observations suggested the involvement of a ‘serpin/enzyme complex (SEC)
receptor’ which was later identified to be LRP-1 [88]. Many serpin : proteinase complexes have been identified
as LRP-1 ligands (see [88,89]). It has been suggested that for most serpins, little LRP-1 binding of monomeric
serpin (native or cleaved) occurs, whereas those in complex with a proteinase are readily endocytosed [88],
implying a common mode of clearing complexes from the extracellular milieu. LRP-1 shedding is increased in
OA cartilage [90], but it is not yet clear how this affects serpin levels within the tissue.
Proteolytic inactivation by MMPs
Interaction between serine and metalloproteinase families is well established as an important factor in the
breakdown of cartilage in arthritis [14], and serpin inactivation by MMPs is another example. Cleavage occurs
within the serpin RCL, removing the bait region and rendering the serpin inactive. In vitro, SerpinA1 and
SerpinA3 are inactivated by MMP1, MMP-2 and MMP-3 [91,92], while SerpinA1 has also been demonstrated
to be inactivated by MMP-9 in vivo [93]. Furthermore, SerpinF2 is rapidly inactivated by MMP-3 [94] and we
have recently demonstrated that MMP-13 — the major OA collagenase — is also able to rapidly inactivate
SerpinA1 (as yet unpublished observations). It is not yet clear what purpose this regulation serves, but it is
likely to have a significant impact on the proteolytic burden in tissues where serine and metalloproteinase activ-
ity is of particular importance, such as the OA joint. Indeed, proteolytic inactivation of serpins in synovial fluid
from arthritis patients has been observed [95,96] but it is unclear the degree to which serpin ‘disarming’ exacer-
bates catabolism. The development of neo-epitope antibodies specific for MMP-cleaved serpins could provide
the foundation for understanding how serpins control the proteolytic environment and how this changes with
the progression of joint destruction in OA.
Discussion: opportunities, challenges and future directions
Our understanding of the role of serine proteinases in cartilage biology and OA has accelerated in recent years,
which prompts re-appraisal of their largest family of endogenous inhibitors. Serpins as a protein family have
been largely overlooked in joint health and disease due — at least in part — to confusing nomenclature. For
example, inhibitory serpins were often given names based on a target which is unlikely to be their major target
in vivo. The likely physiological proteinase target of alpha-1 antitrypsin (SerpinA1) is not trypsin, but rather
neutrophil elastase for which its kinetics are overwhelmingly favourable (Ka = 6.5 × 10
7M−1 s−1; [97]). Recent
standardised nomenclature and separation into clades based on sequence similarities have provided some
clarity, but multiple names has led to many observed changes in serpin transcript or protein levels — identified
through ‘omic technology’ — being largely ignored when ascribing key pathways or proteins in disease
mechanisms [98,99]. Here for the first time, the superfamily is discussed as a whole, in the context of their rela-
tionship with cartilage and OA.
In OA, several studies have demonstrated inhibitory serpins which are markedly down-regulated [21,22,99],
perhaps implying decreased proteolytic inhibition, the potential consequences of which could be uncontrolled
proteolysis. This appears paradoxical, as several serpins (including SerpinA1 [27], SerpinA3 [100], SerpinE1
[101] and SerpinE2 [53]) can be induced by pro-inflammatory cytokines which may also play a role in driving
OA [102,103]. However, it is important to recognise that periodic expression changes do not always mirror
long-term observations in a slow degenerative disease. Furthermore, in an environment where MMPs can
inactivate some serpin family members, total serpin protein is likely an over-representation of functional serpin
levels in the joint. Some serpins are also inactivated by oxidative stress, which is considered a principal driver
of OA [104,105]. SerpinA1, SerpinC1, SerpinE1, SerpinF2 and SerpinG1 are all known to be inactivated by oxi-
dation [106,107]. In the RA joint, SerpinA1 inhibitory activity is depressed [108] and oxidation-associated
inactivation has been observed following exercise [109]. Further work is required to explore the degree to
which serpins are inactivated by proteolysis and oxidation in the OA joint, but both are likely to have a role in
reducing functional inhibitor levels.
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It is likely that changes in the levels of inhibitory serpins could promote cartilage breakdown, through an
increased activity of serine proteinases, which are themselves important in destruction. Proteinases which are
known proMMP activators (reviewed in [14]), and are well established to be controlled by serpin inhibition
include neutrophil elastase, plasmin and proprotein convertases such as furin (see Table 1), although there are
likely to be others. Which serpins are essential for chondroprotection through antiproteinase activity, and the
stage of OA in which they are most important, are yet to be elucidated, however. Using transgenic mice defi-
cient for particular serpins in animal models of OA will help in this endeavour. It should be noted, that some
family members display differences in the number of paralogues between species which will be a significant
hurdle in this respect. For example, whilst humans have one SERPINA1 gene, mice have six members
(Serpina1a-f ), and although humans have one SERPINA3 gene, the mouse has nine paralogues (Serpina3a-c,
f-n). Functional comparisons are limited, but a recent study used CRISPR/Cas9 technology to remove 5
Serpina1 paralogues and demonstrated that mice exhibited lung emphysema [110], reflecting patient phenotype
of the human genetic condition alpha-1 antitrypsin deficiency (AATD), a disorder with significant lung dys-
function due to uncontrolled neutrophil elastase activity. In the future, the use of such mice could inform
studies investigating the effect of Serpina1 deficiency in murine experimental arthritis. Fortunately, for most
serpins, one human gene is mirrored with a single orthologue in rodents, and indeed transgenic animals have
begun to be used successfully to understand the importance of these serpin genes in diseases, including OA
[61,67,74].
Serpins themselves are already licenced for treatments in numerous disorders [5]. Perhaps the most estab-
lished is augmentation therapy for AATD, with weekly IV infusion of SerpinA1 protein derived from pooled
human plasma [111,112]. Another example is the prophylactic treatment of hereditary angioedema with
SerpinG1 (C1 esterase inhibitor; [113]). Should serpin augmentation for arthritic diseases be beneficial, systemic
administration would likely deliver little to the joint capsule — presenting a pharmacokinetic challenge —
although intra-articular injection could be a viable alternative. The unique serpin mechanism lends itself to the
production of recombinant ‘designer serpins’ which may result in altered target specificity or improved stability
[5]. For example, SerpinE1 is a uniquely unstable protein, with a half-life of ∼1–2 h. Four-point mutations can
be made which remarkably increase this time by over 100 h, without significantly compromising serine protein-
ase inhibition, making this mutant more suitable for many research applications [114,115]. It seems likely that
the recombinant production of serpins with improved properties may well influence how these proteins are
used in the future both in a research environment and perhaps also therapeutically.
There is a strong precedent for the successful inhibition of serine proteinases and indeed the use of serpins
themselves to treat a multitude of diseases. With recent evidence solidifying the importance of this protein
superfamily in OA, understanding serpin biology, physiological targets and regulation in these tissues warrants
further investigation and has the potential to offer new insights and pathways to treatment.
Perspectives
• Highlight the importance of the field: Cartilage destruction is central to osteoarthritis, where
an imbalance of proteinases to their inhibitors promotes catabolism. The largest family of
serine proteinase inhibitors are the serpins, an ancient and remarkable superfamily of proteins,
which, despite their likely role in controlling proteolytic pathways, are often ignored in the
context of joint disease.
• A summary of the current thinking: Serpins control the proteolytic activity of serine proteinases
and play a crucial role in normal joint homeostasis. Non-inhibitory activity of serpins also has
important roles in cartilage function, for example in collagen chaperoning.
• A comment on future directions: Serpins represent important mediators for controlling the pro-
teolytic environment. A better understanding of their specific roles in joint biology will be
crucial if this potential is to be harnessed for therapeutic gain in OA; either using serpins
themselves, or as tools to identify particular proteinases which may be of interest for drug
discovery.
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